[1] Li M, Sala V, De Santis MC, Cimino J, Cappello P, Pianca N, Di Bona A, Margaria JP, Martini
M, Lazzarini E, Pirozzi F, Rossi L, Franco I, Bornbaum J, Heger J, Rohrbach S, Perino A, Tocchetti CG,
Lima BHF, Teixeira MM, Porporato PE, Schulz R, Angelini A, Sandri M, Ameri P, Sciarretta S,
Lima-Júnior RCP, Mongillo M, Zaglia T, Morello F, Novelli F, Hirsch E, Ghigo A. Phosphoinositide
3-Kinase Gamma Inhibition Protects From Anthracycline Cardiotoxicity and Reduces Tumor Growth.
Circulation. 2018, 138(7):696-711. (IF: 23.054)
[2] Huang J, Wu R, Chen L, Yang Z, Yan D
#
, Li M
#
. Understanding Anthracycline Cardiotoxicity
From Mitochondrial Aspect. Frontiers in Pharmacology. 2022, 13: 811406. #Corresponding Authors (IF:
5.810)
[3] Zhu B, Zhong W, Cao X, Pan G, Xu M, Zheng J, Chen H, Feng X, Luo C, Lu C, Xiao J, Lin W,
Lai C, Li M, Du X, Yi Q, Yan D. Loss of miR-31-5p drives hematopoietic stem cell malignant
transformation and restoration eliminates leukemia stem cells in mice. Science Translational Medicine.
2022, 14(629):eabh2548. (IF: 17.956)
[4] Zhong W, Cao X, Pan G, Niu Q, Feng X, Xu M, Li M, Huang Y, Yi Q, Yan D. ORP4L is a
prerequisite for the induction of T-cell leukemogenesis associated with human T-cell leukemia virus 1.
Blood. 2022, 139(7):1052-1065. (IF: 22.113)
[5] Li M, Russo M, Pirozzi F, Tocchetti CG, Ghigo A. Autophagy and cancer therapy
cardiotoxicity: From molecular mechanisms to therapeutic opportunities. BBA-Molecular Cell Research.
2020, 1867(3):118493. (IF: 4.739)
[6] Russo M, Guida F, Paparo L, Trinchese G, Aitoro R, Avagliano C, Fiordelisi A, Napolitano F,
Mercurio V, Sala V, Li M, Sorriento D, Ciccarelli M, Ghigo A, Hirsch E, Bianco R, Iaccarino G, Abete P,
Bonaduce D, Calignano A, Berni Canani R, Tocchetti CG. The novel butyrate derivative
phenylalanine-butyramide protects from doxorubicin-induced cardiotoxicity. European Journal of Heart
Failure. 2019, 21(4):519-528. (IF:13.965)
[7] Ghigo A, Laffargue M, Li M, Hirsch E. PI3K and Calcium Signaling in Cardiovascular Disease.
Circulation Research. 2017, 121(3):282-292. (IF: 15.862)
[8] Li M*, Murabito A*, Ghigo A, Hirsch E. PI3Ks in Diabetic Cardiomyopathy. Journal of
Cardiovascular Pharmacology. 2017, 70(6):422-429. *equal contributors (IF: 2.371)
[9] Ghigo A*, Li M*, Hirsch E. New signal transduction paradigms in anthracycline-induced
cardiotoxicity. BBA-Molecular Cell Research. 2016, 1863(7):1916-25. *equal contributors (IF: 4.739)
[10] Li M, Hirsch E. Akt activation by PHLPP1 ablation prevents pathological hypertrophy by
promoting angiogenesis. Cardiovascular Research. 2015, 105:129–130. (IF: 10.787)
[11] Ghigo A, Li M. Phosphoinositide 3-kinase: Friend and foe in cardiovascular disease. Frontiers
in Pharmacology. 2015, 6:169. (IF:3.845)
[12] Li M-C*, Liu Q-Q*, Zhang Y-L, Wang L-L, Lu X-Y. Heterologous expression of human
costimulatory molecule B7-2 and construction of B7-2 Immobilized PHA nanoparticles as immune
activation agent. BMC Biotechnology. 2012, 12:43. *equal contributors (IF: 2.303)
*Equal first contributors, #Corresponding Authors.